Oric Pharmaceuticals (ORIC) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Development priorities and clinical programs

• Focus on small molecule therapies targeting resistance in prostate, lung, and breast cancers.

• Lead programs: rinzimetostat (PRC2 inhibitor) in prostate cancer and enozertinib (EGFR inhibitor) in lung cancer.

• Phase III study for rinzimetostat to start in the first half of the year; dose optimization data expected in Q1.

• Enozertinib phase III study may begin after additional data updates in the second half of the year.

Clinical data and differentiation

• Rinzimetostat showed higher PSA response rates and a more favorable safety profile compared to Pfizer's mevrometostat in early data.

• Differentiation is not required for commercial success in prostate cancer, but early signs suggest potential safety advantages.

• Safety is a significant differentiator due to the community-based treatment setting and long therapy duration.

• Dose optimization update in Q1 will focus on PSA responses and early durability, with 20-25 patients from one study arm.

Strategic and financial outlook

• Decision on AR inhibitor partner for phase III will be based on data and strategic considerations; both apalutamide and darolutamide are viable.

• Fully funded for the first phase III study, with cash runway into the second half of 2028.

• No immediate need for a corporate partner; future partnerships may be considered for broader development.